** Stu's Views & M.S. News **: PML risk factors still inconclusive, says Biogen

ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Tuesday, September 15, 2009

PML risk factors still inconclusive, says Biogen

Reuters - Tue Sep 15, 2009

By Toni Clarke

BOSTON, Sept. 15 (Reuters) - Biogen Idec Inc (BIIB.O) said on Tuesday it would be premature to conclude that the risk of developing a potentially deadly brain infection increases the longer patients take its multiple sclerosis drug Tysabri.

The company told investors at the Morgan Stanley healthcare conference that despite two new reports of patients who have developed progressive multifocal leukoencephalopathy, or PML, it is too early to draw any specific conclusion.

>> READ MORE <<

============================================